ABBV · Healthcare
AbbVie Inc.
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-09-23
- Acquisition / Partnership / DivestitureImportance 58 · Surprise 42AbbVie reportedly pursued the acquisition of Apogee Therapeutics through an $8.0 billion public offering. The transaction is positioned as part of AbbVie’s strategy to expand its drug portfolio and support growth…
- Licensing / Collaboration DealsImportance 46 · Surprise 42AbbVie entered a multi-year research collaboration with Iambic Therapeutics, an AI drug-discovery company backed by Nvidia and Qatar Investment Authority. The collaboration gives AbbVie access to Iambic’s AI platform…
- Regulatory Approval MilestonesImportance 31 · Surprise 42The European Union approved Rinvoq (upadacitinib) for active polyarticular juvenile idiopathic arthritis in patients aged two and older. The approval is Rinvoq’s 11th EU indication and expands AbbVie’s immunology…
News · 2026-09-22
- Acquisition / Partnership / DivestitureImportance 52 · Surprise 42AbbVie made an upfront payment of at least $600 million for rights to a Chinese pharmaceutical asset. The transaction represents a significant investment in AbbVie’s China licensing strategy and exceeds the specified…
- China Licensing StrategyImportance 52 · Surprise 42Third-party reporting said AbbVie made an upfront payment of at least $600 million for rights to a Chinese drug asset. The transaction represents a material expansion of AbbVie's China licensing strategy and carries…
- Regulatory Approval MilestonesImportance 38 · Surprise 60The European Commission approved RINVOQ (upadacitinib) for active polyarticular juvenile idiopathic arthritis in patients aged two years and older who have responded inadequately to, or are intolerant of, one or more…
- Licensing / Collaboration DealsImportance 34 · Surprise 42AbbVie reportedly partnered with Iambic to advance AI-driven drug discovery for small-molecule therapies. The collaboration is intended to support pipeline development, but the digest does not disclose transaction…
- Aesthetic Care Demand TrendsImportance 31 · Surprise 42Allergan Aesthetics launched AA Signature: SKIN360 in the United States as a multimodal consultation program for aesthetic patients. The approach combines Allergan Medical Institute resources with products including…
- China Trial Data InquiryImportance 31 · Surprise 42A U.S. House committee requested information from AbbVie concerning data protection and ethics at the company's clinical-trial sites in China. The inquiry creates potential regulatory, compliance, and…
News · 2026-09-21
- Licensing / Collaboration DealsImportance 31 · Surprise 42AbbVie and Iambic entered a multi-year collaboration on September 21, 2026, focused on AI-driven small-molecule drug discovery. The collaboration covers AbbVie’s immunology, neuroscience, and oncology therapeutic…
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42AbbVie and Iambic entered a multi-year collaboration to apply Iambic’s AI platform to small-molecule drug discovery. The work will focus on immunology, neuroscience, and oncology, using Iambic’s Enchant and…
News · 2026-09-18
- Product / Drug Pipeline ProgressImportance 23 · Surprise 24AbbVie presented prospective real-world data for VRAYLAR (cariprazine) at Psych Congress 2026 in New Orleans. The CReW BP-I study reported significant reductions in depression scores among patients with bipolar I…
- Quarterly Dividend DeclarationImportance 18 · Surprise 14AbbVie declared a quarterly dividend of $1.73 per share for 2026. The dividend represents an annualized yield of approximately 2.7% based on the reported share price. The company’s quarterly payout has increased by…
News · 2026-09-17
- Aesthetic Care Demand TrendsImportance 31 · Surprise 42Allergan Aesthetics announced two single-center clinical studies evaluating targeted skincare regimens in individuals taking medical weight loss medications, including GLP-1 receptor agonists. The studies assess…
- Oncology Pipeline ProgressImportance 31 · Surprise 42AbbVie reported that Phase 3 CERVINO results for etentamig met both dual primary endpoints—objective response rate and progression-free survival—in relapsed or refractory multiple myeloma. The results will be presented…
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42AbbVie said Phase 3 CERVINO results for etentamig met the dual primary endpoints of objective response rate and progression-free survival in relapsed/refractory multiple myeloma. The company will present the data at…
News · 2026-09-15
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42MarketBeat reported that AbbVie is using the Apogee deal to support growth after HUMIRA, with a strategy focused on immunology, neuroscience, oncology and obesity. Executives highlighted plans to expand beyond the…
News · 2026-09-11
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42AbbVie reported positive top-line Phase III LUNA results for atogepant, an oral calcitonin gene-related peptide receptor antagonist. The study met its primary endpoint, demonstrating a statistically significant and…
News · 2026-09-10
- Revenue Performance and MixImportance 60 · Surprise 24Skyrizi and Rinvoq generated more than half of AbbVie’s total revenue in the first half of 2026, according to third-party reporting. The products replaced revenue lost from Humira biosimilar erosion. AbbVie anticipates…
- Immunology Product Demand and ExpansionImportance 60 · Surprise 24AbbVie’s immunology franchise is being driven by Skyrizi and Rinvoq, which a third-party report described as generating more than half of AbbVie’s revenue in the first half of 2026. The products have offset revenue…
- Acquisition / Partnership / DivestitureImportance 58 · Surprise 42AbbVie’s collaboration with ADARx Pharmaceuticals provided ADARx with $335 million in upfront cash. The agreement includes $385 million in option payments and up to $7.45 billion in milestone payments, plus royalties.…
- Licensing / Collaboration DealsImportance 58 · Surprise 42AbbVie’s collaboration with ADARx Pharmaceuticals is supporting development of RNA-targeted therapies for hepatic and non-hepatic diseases. The agreement provided ADARx with $335 million in upfront cash and $385…
- Product Pipeline ProgressImportance 31 · Surprise 42AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. Patients receiving atogepant experienced 0.8 fewer migraine days associated with the menstrual period than placebo…
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment reduced menstrual-period migraine days by 0.8 days versus placebo and achieved the primary endpoint…
- Quarterly Dividend DeclarationImportance 13 · Surprise 6AbbVie’s board declared a quarterly cash dividend of $1.73 per share on September 10, 2026. The dividend is payable on November 16, 2026, to stockholders of record at the close of business on October 15, 2026. The…
News · 2026-09-09
- Acquisition / Partnership / DivestitureImportance 61 · Surprise 60AbbVie issued US$10 billion of bonds in August to help fund its US$10.9 billion all-cash acquisition of Apogee Therapeutics. The nine tranches mature between 2028 and 2066 and may also fund general corporate purposes…
- Guidance / OutlookImportance 59 · Surprise 32At a Wells Fargo conference, AbbVie maintained its expectation for high-single-digit annual revenue growth through the decade. Management identified new indications for SKYRIZI and RINVOQ as significant growth drivers…
- Product / Drug Pipeline ProgressImportance 29 · Surprise 30AbbVie identified continued growth of its SKYRIZI and RINVOQ immunology franchises as core commercial drivers. The company expects additional growth from new indications for these immunology medicines. AbbVie also…
News · 2026-09-08
- Cash Flow and Capital AllocationImportance 38 · Surprise 24A third-party report stated that AbbVie returned approximately $62 billion to shareholders through dividends and buybacks over the five years ended September 2026. The reported capital returns were supported by free…
News · 2026-09-04
- Cash Flow and Capital AllocationImportance 38 · Surprise 24A third-party report stated that AbbVie returned approximately $62 billion to shareholders through dividends and buybacks over the five years ended September 2026. The reported capital returns were supported by free…
8-K · 2026-09-03
- Acquisition / Partnership / DivestitureImportance 71 · Surprise 60AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026, bringing Apogee into AbbVie. Apogee shareholders received $135.11 per share in cash, representing total equity value of approximately $10.9…
- Guidance / OutlookImportance 36 · Surprise 24AbbVie reaffirmed its 2026 full-year adjusted diluted EPS guidance range of $13.87 to $14.07. The full-year guidance includes a $0.14 per-share dilution from the completed Apogee acquisition and a $0.58 per-share…
- Product / Drug Pipeline ProgressImportance 30 · Surprise 42Apogee adds late-stage and early-stage antibody programs targeting atopic dermatitis, asthma and other inflammatory diseases to AbbVie's immunology pipeline. Zumilokibart, an IL-13 antibody in development for atopic…
- Immunology Product Demand and ExpansionImportance 17 · Surprise 24AbbVie identified an unmet need in atopic dermatitis because a majority of patients do not achieve simultaneous itch relief and skin improvement. In zumilokibart’s Phase 2 trial, approximately two-thirds of treated…
News · 2026-09-03
- Acquisition / Partnership / DivestitureImportance 71 · Surprise 60AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics on September 3, 2026. The transaction adds zumilokibart, a late-stage half-life-extended IL-13 antibody for atopic dermatitis, and…
- Product / Drug Pipeline ProgressImportance 58 · Surprise 82AbbVie’s investigational etentamig met both primary endpoints in the Phase 3 CERVINO trial for triple-class-exposed patients with relapsed/refractory multiple myeloma. The BCMA x CD3 bispecific T-cell engager produced…
- Oncology Pipeline ProgressImportance 58 · Surprise 82AbbVie reported positive topline Phase 3 CERVINO results for etentamig, an investigational BCMA×CD3 bispecific T-cell engager in triple-class-exposed relapsed or refractory multiple myeloma. Etentamig produced a 74%…
- Cash Flow and Capital AllocationImportance 38 · Surprise 24A third-party report stated that AbbVie returned approximately $62 billion to shareholders through dividends and buybacks over the five years ended September 2026. The reported capital returns were supported by free…
- Guidance / OutlookImportance 36 · Surprise 24AbbVie reaffirmed its full-year 2026 adjusted diluted EPS guidance range of $13.87 to $14.07. It also reaffirmed third-quarter 2026 adjusted diluted EPS guidance of $3.84 to $3.88. The reaffirmation followed completion…
- Regulatory Approval MilestonesImportance 31 · Surprise 42Third-party reporting said AbbVie submitted a European regulatory application for a subcutaneous induction option in its immunology franchise. The proposed option targets Crohn’s disease and is intended to provide a…
News · 2026-09-02
- Aesthetic Care Demand TrendsImportance 17 · Surprise 24Allergan Aesthetics’ Layered Beauty report surveyed more than 12,000 consumers across nine global markets. The research identified growing interest in personalized, long-term aesthetic plans rather than isolated…
News · 2026-09-01
- Product Launch and TransitionImportance 54 · Surprise 74Allergan Aesthetics launched SkinMedica Barrier Calming Cream, a regenerative skincare product intended to restore and fortify the skin barrier. The product uses Calcium Strengthening Complex and Botanical Calming…
News · 2026-08-29
- Guidance / OutlookImportance 47 · Surprise 60AbbVie trimmed its full-year 2026 EPS guidance slightly after reporting second-quarter results. The revision indicates a more cautious management outlook despite Q2 revenue of $16.99 billion exceeding consensus…
- Revenue Performance and MixImportance 32 · Surprise 6AbbVie reported second-quarter 2026 revenue of $16.99 billion, exceeding consensus estimates. Adjusted EPS was $3.65, also above consensus, with both revenue and adjusted EPS showing significant year-over-year growth.…
- Immunology Product Demand and ExpansionImportance 8 · Surprise 24Skyrizi continued to drive AbbVie’s Immunology segment in the second quarter of 2026. The report identifies Skyrizi as a key growth product within AbbVie’s immunology portfolio. No additional customer, geographic,…
News · 2026-08-28
- Product Launch and TransitionImportance 31 · Surprise 42AbbVie is seeking European Union approval for a subcutaneous induction option of Skyrizi in Crohn’s disease. The formulation could provide patients with a more convenient administration option than the existing…
- Regulatory Approval MilestonesImportance 31 · Surprise 42AbbVie is seeking European Union approval for a subcutaneous induction option of Skyrizi (risankizumab) for Crohn’s disease. The proposed option could provide patients with a more convenient administration route during…
News · 2026-08-27
- Competition and Market PositionImportance 40 · Surprise 42China’s drug regulator approved Johnson & Johnson’s oral psoriasis treatment Icotyde on August 27, 2026. The approval intensifies competition in China’s moderate-to-severe plaque psoriasis market, where Icotyde will…
- Regulatory Approval MilestonesImportance 34 · Surprise 42AbbVie submitted an application to the European Medicines Agency on August 27, 2026, seeking approval for subcutaneous induction of SKYRIZI (risankizumab) in adults with moderately to severely active Crohn’s disease.…
News · 2026-08-26
- Product / Drug Pipeline ProgressImportance 34 · Surprise 42AbbVie initiated a Phase 2 clinical study for an obesity drug partnered with Gubra on August 26, 2026. The study triggered a $50 million milestone payment to Gubra. The program expands AbbVie’s metabolic-disease…
News · 2026-08-25
- Guidance / OutlookImportance 51 · Surprise 60Third-party reporting states that AbbVie raised its full-year 2026 EPS guidance following strong second-quarter 2026 earnings. The report says the updated outlook, together with growth in immunology products,…
- Oncology Pipeline ProgressImportance 34 · Surprise 42AbbVie’s evolving oncology pipeline is identified as a component of its longer-term portfolio strategy. The company reportedly experienced a setback in a key oncology trial, creating development risk despite broader…
- Competition and Market PositionImportance 13 · Surprise 6Eli Lilly is gaining momentum in obesity and diabetes through its GLP-1 therapies Mounjaro and Zepbound. AbbVie has offset Humira’s loss of exclusivity with immunology products Skyrizi and Rinvoq. The comparison…
News · 2026-08-24
- Revenue Performance and MixImportance 69 · Surprise 64AbbVie’s second-quarter 2026 net revenue increased 10.2% year over year to $16.990 billion, exceeding the materiality threshold and qualifying under the 10% change rule. Immunology demand for Skyrizi and Rinvoq more…
- Guidance / OutlookImportance 44 · Surprise 60AbbVie lowered its full-year 2026 adjusted diluted EPS guidance. The reduction reflects the anticipated acquisition of Apogee Therapeutics, although the reported coverage does not provide the acquisition consideration…
- Acquisition / Partnership / DivestitureImportance 31 · Surprise 42AbbVie is anticipating the acquisition of Apogee Therapeutics. The Apogee transaction prompted AbbVie to lower its full-year adjusted EPS guidance. The digest does not provide the acquisition consideration, closing…
- Net Income and ProfitabilityImportance 24 · Surprise 30Q2 2026 adjusted diluted EPS rose 22.9% year over year to $3.65. The EPS increase accompanied 10.2% growth in net revenue to $16.990 billion. The reported earnings improvement was supported by Skyrizi and Rinvoq growth…
News · 2026-08-22
- Guidance / OutlookImportance 51 · Surprise 60Third-party reporting said AbbVie raised its full-year 2026 guidance following reported second-quarter growth. The outlook was supported particularly by immunology medicines SKYRIZI and RINVOQ and by continued…
- Revenue Performance and MixImportance 37 · Surprise 6AbbVie reported second-quarter 2026 revenue of $16.99 billion and earnings of $3.65 per share. Second-quarter growth was led particularly by the immunology medicines SKYRIZI and RINVOQ. The reported results exceeded…
News · 2026-08-21
- Oncology Pipeline ProgressImportance 31 · Surprise 42AbbVie will present new clinical data at the 2026 World Conference on Lung Cancer (WCLC) across non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The portfolio includes investigational ABBV-1480…